Role of alpha-adrenoceptors and prostacyclin in the enhanced adrenergic reactivity of goat cerebral arteries after ischemia-reperfusion.
To analyze ischemia-reperfusion effects on the cerebrovascular adrenergic response, the left middle cerebral artery (MCA) of anesthetized goats was occluded for 120 min and reperfused for 60 min. Isolated segments from the left (ischemic) and right (control) MCA exhibited isometric constriction in response to noradrenaline (10(-8)-10(-4)M, in the presence of beta-adrenoceptors blockade), phenylephrine (alpha(1)-adrenoceptors agonist, 10(-8)-10(-4)M), B-HT-920 (alpha(2)-adrenoceptors agonist, 10(-7) - 3 x 10(-3)M) or tyramine (indirect sympatheticomimetic amine, 10(-8)-10(-4)M), but this constriction was greater in ischemic arteries. The cyclooxygenase (COX) inhibitor meclofenamate (10(-5)M) augmented the response to noradrenaline only in control arteries. The prostacyclin (PGI(2)) synthesis inhibitor tranylcypromine (TCP, 10(-5)M) increased the response to noradrenaline in control arteries and reduced it in ischemic arteries. The thromboxane A(2) (TXA(2)) synthase inhibitor furegrelate (10(-6)M) did not modify the noradrenaline effect in both types of arteries, whereas the TXA(2) receptor antagonist SQ 29 548 (10(-5)M) and the COX-2 inhibitor NS-398 (10(-6)M) decreased the response to noradrenaline only in ischemic arteries. PGI(2) caused a small relaxation in control arteries and a small contraction in ischemic arteries. alpha-Adrenoceptors and COX-2 protein expression and the metabolite of PGI(2) were augmented in ischemic arteries. Therefore, ischemia-reperfusion may increase the cerebrovascular responsiveness to noradrenaline, through upregulation of alpha-adrenoceptors and increased COX-2-derived PGI(2) exerting a vasoconstrictor action. After ischemia-reperfusion, noradrenaline might increase PGI(2) production thus contributing to adrenergic vasoconstriction and/or PGI(2) would potentiate the noradrenaline effects.
Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma, 28029 Madrid, Spain.
Luis
L
Monge
Nuria
N
Fernández
Adely
A
Salcedo
Angel Luis
AL
García-Villalón
Godofredo
G
Diéguez
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D002536:Cerebral Arteries / Q000502:physiology*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D006041:Goats; D006439:Hemodynamics / Q000502:physiology; D066298:In Vitro Techniques; D020768:Middle Cerebral Artery / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011189:Potassium Chloride / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D044244:Receptors, Thromboxane A2, Prostaglandin H2 / Q000037:antagonists & inhibitors; D015427:Reperfusion Injury / Q000503:physiopathology*; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D052246:Cyclooxygenase 2 Inhibitors; D011942:Receptors, Adrenergic, alpha; D044244:Receptors, Thromboxane A2, Prostaglandin H2; D014662:Vasoconstrictor Agents; D011189:Potassium Chloride; D011464:Epoprostenol